TLE

EY Announces Richard Weissman of The Learning Experience as an Entrepreneur Of The Year® 2023 Florida Award Winner

Retrieved on: 
Tuesday, June 13, 2023
Ernst & Young Entrepreneur of the Year Award, National Film Awards, Education, EY, Ewing Marion Kauffman Foundation, PNC Financial Services, Side platform, Learning, Entrepreneurship, SAP, Cresa, Growth, Piper, Courage, Family, DLA Piper, TLE, Ernst & Young, Toy, Nursing, Management

DEERFIELD BEACH, Fla., June 13, 2023 /PRNewswire/ -- Ernst & Young LLP (EY US) today announced that Richard Weissman, Chairman, CEO and Co-Founder of The Learning Experience® (TLE®) was named an Entrepreneur Of The Year® 2023 Florida Award winner. The Entrepreneur Of The Year Awards program is one of the preeminent competitive awards for entrepreneurs and leaders of high-growth companies. Weissman was selected by an independent judging panel made up of previous award winners, leading CEOs, investors and other regional business leaders. The candidates were evaluated based on their demonstration of building long-term value through entrepreneurial spirit, purpose, growth and impact, among other core contributions and attributes.

Key Points: 
  • DEERFIELD BEACH, Fla., June 13, 2023 /PRNewswire/ -- Ernst & Young LLP (EY US) today announced that Richard Weissman, Chairman, CEO and Co-Founder of The Learning Experience® (TLE®) was named an Entrepreneur Of The Year® 2023 Florida Award winner.
  • "I am incredibly humbled and honored to be named an Entrepreneur Of The Year 2023 Florida Award winner," said Weissman.
  • As a Florida award winner, Weissman is now eligible for consideration for the Entrepreneur Of The Year 2023 National Awards.
  • The Entrepreneur Of The Year National Overall Award winner will then move on to compete for the World Entrepreneur Of The Year® Award in June 2024.

uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

Retrieved on: 
Tuesday, November 29, 2022
Research, Temporal lobe epilepsy, Patient, Epilepsy, Head, Seizure, Compte rendu, Gene, Harvard Medical School, IND, Temporal lobe, Safety, Knowledge, Fabry disease, Brain, Primate, Learning, Mortality, Neoplasm, Annual report, GRIK2, GLP, Central nervous system, MD, TLE, CNS, Webcast, Disease, Risk, Health, Memory, Birth defect, Huntington's disease, Neurology, Hope, MicroRNA, Haemophilia, AAV, Hippocampus, Neuron, FDA, Movement disorders, Pharmaceutical industry, Vaccine, Medical device, Brigham

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epilepsies. The event featured a presentation from rTLE clinical expert Ellen Bubrick, MD, associate chair of Neurology at Harvard Medical School and director of the Epilepsy Surgery Program at Brigham and Women’s Hospital in Boston, MA on the unmet medical need of patients with rTLE. The presentation highlighted preclinical data that supports the safety and tolerability of AMT-260 and plans for its clinical development, as well as uniQure’s miQURE™ and linQURE™ technology platforms that allow the Company to use miRNAs to safely reduce the expression of genes in the brain. The Company also highlighted its progress in developing a commercial-scale AAV manufacturing platform. A replay of the investor event is available here.

Key Points: 
  • The full virtual research and development event program was webcast live under the Investors section of uniQures website at www.uniQure.com .
  • Temporal lobe epilepsy (TLE) is epilepsy that starts in the temporal lobe area of the brain.
  • About 80% of all temporal lobe seizures start in the mesial temporal lobe, with seizures often starting in or near the hippocampus which controls memory and learning.
  • Patients with refractory temporal lobe epilepsy (rTLE) experience increased morbidity, excess mortality, and poor quality of life.

New Survey: Military Families Facing Crippling Housing, Moving Costs

Retrieved on: 
Friday, October 21, 2022
Online, Congress, Electricity, DOD, Joint base, Sleep, Research, United States Department of Defense, Knowledge, Recreational vehicle, Ensuring Public Involvement in the Creation of National Monuments Act, Human, Basic Allowance for Housing, Department, CEO, NDAA, TLE, National Defense Authorization Act for Fiscal Year 2013, BAH, Internet, Solution, National security, Language, Health insurance, Housing

WASHINGTON, Oct. 21, 2022 /PRNewswire/ -- Today, Blue Star Families released a new survey that paints a dire situation facing many military families across the country. Conducted from September 16-21 with over 2,200 respondents, the new research shows that a majority of active-duty families are facing serious issues related to lengthy stays in temporary lodging due to a limited housing market and skyrocketing housing costs.

Key Points: 
  • WASHINGTON, Oct. 21, 2022 /PRNewswire/ -- Today, Blue Star Families released a new survey that paints a dire situation facing many military families across the country.
  • The results showed the following:
    On average, military families face over $6,000 in unreimbursed costs in the first year of relocation alone.
  • Blue Star Families is the nation's largest grass-roots military family support organization, with a mission to support military families to improve military readiness.
  • Blue Star Families' nationally recognized surveys and analysis give military families an important voice that informs policymakers and its military family programs.

uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 11, 2022
Congress, Fabry disease, ESGCT, European Society of Gene and Cell Therapy, Cell, NASDAQ, Patient, Gene, Research, ALS, Technology, Haemophilia, Company, TLE, Huntington's disease, GLOBE, Forward-looking statement, Temporal lobe epilepsy, Pharmaceutical industry

and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress taking place this week in Edinburgh, UK (October 11-14, 2022).

Key Points: 
  • and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress taking place this week in Edinburgh, UK (October 11-14, 2022).
  • Our presentations at ESGCT highlight both uniQures exciting pipeline of gene therapy candidates and our leading gene therapy manufacturing and administration capabilities, stated Ricardo Dolmetsch, president of research & development at uniQure.
  • Specific details on uniQures poster presentations at ESGCT include:
    Title: Enhancing efficacy and specificity of rAAV5 via small, intermediate, and large peptide insertions
    uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.
  • Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release.

Worldwide Kainic Acid Industry to 2027 - Featuring Abcam, Alfa Chemistry and Cayman Chemical Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Pharmaceutical, WHO, World Health Organization, Temporal lobe epilepsy, Kainic acid, Incidence, Prevalence, Epilepsy, World, Government, TLE, Epileptic Disorders, Pharmaceutical industry, Marketing

This rising prevalence of epilepsy disorder around the globe is expected to drive the global kainic acid market.

Key Points: 
  • This rising prevalence of epilepsy disorder around the globe is expected to drive the global kainic acid market.
  • The global kainic acid market is segmented based on type and application.
  • Based on type, the kainic acid market is segmented into high purity (above 99%), low purity (below 97%), purity (above 97% and below 99%) kainic acid.
  • Analysis of regional regulations and other government policies impacting the global kainic acid market.

Minister of Crown-Indigenous Relations meets virtually with First Nations leadership and partners in Manitoba

Retrieved on: 
Thursday, January 20, 2022
Mathias Colomb First Nation, Research, Assembly, Entitlement, West Region Tribal Council, Couch, ISC, Assembly of Manitoba Chiefs, COVID-19, Lake Manitoba First Nation, Fox Lake Cree Nation, Nation, Minister of Crown–Indigenous Relations, First Nations, Leadership, SCO, Sixties Scoop, Housing, Treaty, Keewatin Tribal Council, AMC, TLE, Tribal Council, Indigenous self-government in Canada, Grand, Organization, Partnership, Woman, Indigenous rights, Online gambling, Indigenous

Also, the Minister met with the Keewatin Tribal Council for a conversation on topics such as self-determination, COVID-19, housing and economic development opportunities.

Key Points: 
  • Also, the Minister met with the Keewatin Tribal Council for a conversation on topics such as self-determination, COVID-19, housing and economic development opportunities.
  • The Minister then met with Manitoba Keewatinowi Okimakanak Grand Chief Garrison Settee on issues most relevant to northern Manitoba First Nations.
  • The Minister then met with leadership of Fox Lake Cree Nation on the First Nation's Recognition of Indigenous Rights and Self-Determination discussion table and their Treaty Land Entitlement Claim.
  • Lastly, Minister Miller met with the Treaty Land Entitlement Committee, along with representatives of Entitlement First Nations signatory to the Treaty Land Entitlement Framework Agreement.

Neuroregenerative Gene Therapy Treats Temporal Lobe Epilepsy in Rat Model

Retrieved on: 
Tuesday, January 4, 2022
Science, Progress in Neurobiology, Seizure, AAV, Hope, Associate, Hippocampus, Brain, Epilepsy, Interneuron, Stroke, Government budget balance, National Natural Science Foundation of China, Neuron, RATS, Lists of diseases, Astrocyte, Huntington's disease, GABAergic, NEUROD1, TLE, Research, Cell, Anticonvulsant, Temporal lobe epilepsy, Jinan University, Patient, Qi, Police Technology Department, Technology, Progress, Animal, Pharmaceutical industry, Vaccine, Neuroscience

In recent years, Chen's team has developed a novel neuroregenerative gene therapy that offers a potential new approach to treat a variety of neurological disorders.

Key Points: 
  • In recent years, Chen's team has developed a novel neuroregenerative gene therapy that offers a potential new approach to treat a variety of neurological disorders.
  • Neuroregenerative gene therapy is a new technology that uses viral vectors to deliver neural transcription factors to glial cells in the brain and directly convert glial cells into functional neurons in situ.
  • "This is the first time we apply neuroregenerative gene therapy to treat epilepsy and achieved success in animal models.
  • This new discovery has important guidance for future clinical applications using neuroregenerative gene therapy to treat different neurological disorders", Professor Chen pointed out the potential clinical significance of this study.

Flushing Bank Partners with The Lonely Entrepreneur to Offer Free Entrepreneur Learning to Minority Business Owners

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Ice, Forward-looking statement, Company, GLOBE, Securities Act of 1933, Knowledge, Learning, ESPN, Security (finance), Federal Deposit Insurance Corporation, Private Securities Litigation Reform Act, Lonely, Doral Financial Corporation, UPS, Social responsibility, Securities Exchange Act of 1934, Partnership, Nasdaq, Life, Molson Coors Beverage Company, Flushing, Sterling Bank, Program, TLE, Equal housing lender, Safe harbor, Solution, Risk, Microsoft, Investment, Tutoring

As a community bank, we recognize the significant role small businesses play in the economic performance of our local communities.

Key Points: 
  • As a community bank, we recognize the significant role small businesses play in the economic performance of our local communities.
  • Our partnership will make the TLE Learning Community platform available to entrepreneurs in Elmhurst and Jamaica, our two newest markets.
  • Selected entrepreneurs will receive one-year free access to the TLE Learning Community to help them advance their business.
  • We want to thank the team at Flushing Bank for providing these minority entrepreneurs with free access to the resources they need to start or scale a business.

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, October 25, 2021
Safety, Efficiency, Disease, BLA, GRIK2, ESGCT, Spinal cord, Cell, Marketing, Hippocampus, IPSC, Clinical trial, COVID-19, Temporal lobe epilepsy, Gene, Program, Acquisition, D, GLOBE, Locomotion, Liver, Spinocerebellar ataxia, Phase, Research, Neuron, SVB Leerink, Type III, Food, Mirna, Data monitoring committee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Annual report, Risk, Company, Hercules, Epilepsy, DSMB, Industry, CSL Behring, TLE, CSL, Sale, Heart, ALS, AAV, C9orf72, Fabry disease, Annual general meeting, Haemophilia, Technology, Huntington's disease, Patient, NASDAQ, FDA, Conference, Kidney, FIX, European Society of Gene and Cell Therapy, Forward-looking statement, Development, Animal, Pharmaceutical industry, Medical device, Vaccine, Cryptocurrency, Reinsurance

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.
  • Along with our global partner, CSL Behring, the Company expects to announce top-line data from the HOPE-B trial in the late fourth quarter of 2021.
  • As part of these efforts, the Company anticipates completing the validation of its commercial manufacturing process before year-end 2021.
  • In July 2021, the Company closed the acquisition of Corlieve Therapeutics, a pre-clinical gene therapy company based in France.

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 19, 2021
ALS, AAV, Nociception, IND, Annual general meeting, GLA, Liver, European Society of Gene and Cell Therapy, NASDAQ, CNS, Neuron, GB3, Technology, Gene, COVID-19, Kidney, Cell, Fabry disease, Haemophilia, Spinal cord, Time, TLE, Type III, CEST, Disease, Epilepsy, Central nervous system, IPSC, Program, Research, C9orf72, Spinocerebellar ataxia, Risk, GLOBE, Brain, Patient, Huntington's disease, Temporal lobe epilepsy, ESGCT, Forward-looking statement, Efficiency, Heart, Phenotype, Locomotion, GRIK2, Pharmaceutical industry, Vaccine

and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.
  • AMT-191 is a one-time administered AAV5 gene therapy incorporating an -galactosidase A (GLA) transgene.
  • Moreover, pre-clinical studies in non-human primates with AMT-191 demonstrated robust and sustained increases in GLA activity in multiple organs.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.